Redeye remains positive to Nekkar’s on the back of a Q4’24 report that beat our forecast, mainly driven by Syncrolift and Globetech. Following the report, we adjust our financial forecast somewhat expecting a 2025 largely in line with 2024. However, the tender pipeline is significant and could easily offset our current estimates following new contract wins. We remain positive to the share, arguing that it continues to be mispriced.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/